Going beyond EGFR

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Zimmermann, S ^a   Peters, S ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Driver mutations; Lung cancer; Oncogenic pathways

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; AFATINIB; ANAPLASTIC LYMPHOMA KINASE; AP 26113; B RAF KINASE; BEVACIZUMAB; BUPARLISIB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOCETAXEL; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GANETESPIB; GEMCITABINE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IPI 204; LAPATINIB; LDK 378; PACLITAXEL; PEMETREXED; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PICTILISIB; SORAFENIB; TRAMETINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; DRUG DOSE ESCALATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; ONCOGENE K RAS; ONCOGENE NEU; OVERALL SURVIVAL; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; ROS1 GENE; TREATMENT OUTCOME; TUMOR GENE;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; ONCOGENE PROTEINS, FUSION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MET; RAS PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 84866769369     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds319     Document Type: Article

References (73)

1. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
2. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
3. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
4. Sequist LV, Heist RS, Shaw AT et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-2624.
5. Sun Y, Ren Y, Fang Z et al. Lung adenocarcinoma from East Asian neversmokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 2010; 28: 4616-4620.
6. Kris MG, Johnson BE, Kwiatkowski DJ et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 2011; 29(suppl) (abstr. CRA7506).
7. Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18: 378-381.
8. Kohno T, Ichikawa H, Totoki Y et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012; 18: 375-377.
9. Capelletti M, Lipson D, Otto G et al. Discovery of recurrent KIF5B-RET fusions and other targetable alterations from clinical NSCLC specimens. J Clin Oncol 2012; 30(suppl) (abstr. 7510).
10. Togashi Y, Soda M, Sakata S et al. KLC1-ALK: A Novel Fusion in Lung Cancer Identified Using a Formalin-Fixed Paraffin-Embedded Tissue Only. PLoS One 2012; 7: e31323.
11. Govindan R, Hammerman PS, Hayes DN et al. Comprehensive genomic characterization of squamous cell carcinoma of the lung. J Clin Oncol 2012; 30 (suppl) (abstr. 7006).
12. Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007; 131: 1190-1203.
13. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
14. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27: 4247-4253.
15. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
16. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011; 12: 1004-1012.
17. Choi YL, Soda M, Yamashita Y et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010; 363: 1734-1739.
18. Sasaki T, Koivunen J, Ogino A et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011; 71: 6051-6060.
19. Lovly CM, Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012; 4: 120ps122.
20. Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol 2011; 7: 817-825.
21. Turke AB, Zejnullahu K, Wu YL et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
22. Katayama R, Shaw AT, Khan TM et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med 2012; 4: 120ra117.
23. Katayama R, Khan TM, Benes C et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011; 108: 7535-7540.
24. Doebele RC, Pilling AB, Aisner DL et al. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res 2012; 18: 1472-1482.
25. Pao W, Miller VA, Politi KA et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2: e73.
26. Doebele RC, Aisner DL, Le AT et al. Analysis of resistance mechanisms to ALK kinase inhibitors in ALK+ NSCLC patients. J Clin Oncol 2012; 30(suppl) (abstr. 7504)
27. Heuckmann JM, Holzel M, Sos ML et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011; 17: 7394-7401.
28. Kamal A, Thao L, Sensintaffar J et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-410.
29. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10: 537-549.
30. Bergethon K, Shaw AT, Ignatius Ou SH et al. ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers. J Clin Oncol 2012; 30: 863-870.
31. El-Deeb IM, Park BS, Jung SJ et al. Design, synthesis, screening, and molecular modeling study of a new series of ROS1 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett 2009; 19: 5622-5626.
32. Shaw AT, Camidge DR, Engelman JA et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol 2012; 30(suppl) (abstr. 7508).
33. Naoki K, Chen TH, Richards WG et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res 2002; 62: 7001-7003.
34. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
35. Sasaki H, Kawano O, Endo K et al. Uncommon V599E BRAF mutations in Japanese patients with lung cancer. J Surg Res 2006; 133: 203-206.
36. Marchetti A, Felicioni L, Malatesta S et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 2011; 29: 3574-3579.
37. Paik PK, Arcila ME, Fara M et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011; 29: 2046-2051.
38. Yang H, Higgins B, Kolinsky K et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010; 70: 5518-5527.
39. Wan PT, Garnett MJ, Roe SM et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855-867.
40. Pratilas CA, Hanrahan AJ, Halilovic E et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68: 9375-9383.
41. Corcoran RB, Settleman J, Engelman JA. Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2011; 2: 336-346.
42. Yang H, Higgins B, Kolinsky K et al. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer. Cancer Res 2012; 72: 779-789.
43. Prahallad A, Sun C, Huang S et al. Unresponsiveness of colon cancer to BRAF (V600E) inhibition through feedback activation of EGFR. Nature 2012; 483: 100-103.
44. Ahrendt SA, Decker PA, Alawi EA et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 2001; 92: 1525-1530.
45. Brugger W, Triller N, Blasinska-Morawiec M et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4113-4120.
46. Smit EF, Dingemans AM, Thunnissen FB et al. Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report. J Thorac Oncol 2010; 5: 719-720.
47. Printz C. BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery. Cancer 2010; 116: 3307-3308.
48. Liu L, Shao X, Gao W et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol 2010; 5: 1922-1932.
49. Shigematsu H, Takahashi T, Nomura M et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005; 65: 1642-1646.
50. Shimamura T, Ji H, Minami Y et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 2006; 66: 6487-6491.
51. Wang SE, Narasanna A, Perez-Torres M et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25-38.
52. Bunn PA, Jr., Helfrich B, Soriano AF et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001; 7: 3239-3250.
53. Gatzemeier U, Groth G, Butts C et al. Randomized phase II trial of gemcitabinecisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004; 15: 19-27.
54. Ross HJ, Blumenschein GR, Jr., Aisner J et al. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res 2010; 16: 1938-1949.
55. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 2006; 354: 2619-2621.
56. De Greve J, Teugels E, Geers C et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 2012; 76: 123-127.
57. Kawano O, Sasaki H, Endo K et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 2006; 54: 209-215.
58. Bader AG, Kang S, Vogt PK. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci USA 2006; 103: 1475-1479.
59. Kawano O, Sasaki H, Okuda K et al. PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 2007; 58: 159-160.
60. Chaft JE, Arcila ME, Paik PK et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol Cancer Ther 2012; 11: 485-491.
61. Di Nicolantonio F, Arena S, Tabernero J et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120: 2858-2866.
62. Onozato R, Kosaka T, Kuwano H et al. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 2009; 4: 5-11.
63. Beau-Faller M, Ruppert AM, X Voegeli AC et al. MET gene copy number in nonsmall cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naive cohort. J Thorac Oncol 2008; 3: 331-339.
64. Otsuka T, Takayama H, Sharp R et al. c-Met autocrine activation induces development of malignant melanoma and acquisition of the metastatic phenotype. Cancer Res 1998; 58: 5157-5167.
65. Bean J, Brennan C, Shih JY et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-20937.
66. Ding L, Getz G, Wheeler DA et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455: 1069-1075.
67. Ma PC, Jagadeeswaran R, Jagadeesh S et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005; 65: 1479-1488.
68. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
69. Graveel C, Su Y, Koeman J et al. Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. Proc Natl Acad Sci USA 2004; 101: 17198-17203.
70. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012; 9: 314-326.
71. Sequist LV, von Pawel J, Garmey EG et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29: 3307-3315.
72. Scagliotti GV, Novello S, Schiller JH et al. Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non-Small-Cell Lung Cancer. Clin Lung Cancer 2012 March 23 [epub ahead of print], doi: 10.1016/j.cllc.2012.01.003.
73. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol 2009; 625: 131-142.